Dr. Mann on Differences Between Treatments for Prostate Cancer

Mark J. Mann, MD, assistant professor, Sidney Kimmel Cancer Center, Thomas Jefferson Hospital, discusses the differences between treatment options for patients with prostate cancer subtypes.

For patients with nonmetastatic castration-sensitive prostate cancer, treatment options have been standardized for a long time with androgen deprivation therapy. However, in nonmetastatic castration-resistant prostate cancer (CRPC), studies have not shown many effective treatment options until recently, says Mann. Studies have investigated denosumab (Xgeva), which did not show any efficacy, and zoledronic acid, which showed a similar response.

With newer imaging modalities, a question is whether a patient is really nonmetastatic, explains Mann. Gallium-68 PET/CT scans identify metastatic disease that was previously not visible. That is likely to change the nonmetastatic castration-sensitive and nonmetastatic CRPC treatment landscape. According to Mann, physicians should consider using drugs from the STAMPEDE and LATITUDE trials.